Immune Checkpoint Blockades in Triple-Negative Breast Cancer: Current State and Molecular Mechanisms of Resistance
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Hyungjoo | - |
dc.contributor.author | Choi, Je-Min | - |
dc.contributor.author | Lee, Kyung-min | - |
dc.date.accessioned | 2022-07-06T02:59:55Z | - |
dc.date.available | 2022-07-06T02:59:55Z | - |
dc.date.created | 2022-06-03 | - |
dc.date.issued | 2022-05 | - |
dc.identifier.issn | 2227-9059 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/138618 | - |
dc.description.abstract | Immune checkpoint blockades (ICBs) have revolutionized cancer treatment. Recent studies have revealed a subset of triple-negative breast cancer (TNBC) to be considered as an immunogenic breast cancer subtype. Characteristics of TNBC, such as higher mutation rates and number of tumor-infiltrating immune cells, render the immunogenic phenotypes. Consequently, TNBCs have shown durable responses to ICBs such as atezolizumab and pembrolizumab in clinic. However, a significant number of TNBC patients do not benefit from these therapies, and mechanisms of resistance are poorly understood. Here, we review biomarkers that predict the responsiveness of TNBCs to ICB and recent advances in delineating molecular mechanisms of resistance to ICBs. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | MDPI | - |
dc.title | Immune Checkpoint Blockades in Triple-Negative Breast Cancer: Current State and Molecular Mechanisms of Resistance | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Choi, Je-Min | - |
dc.contributor.affiliatedAuthor | Lee, Kyung-min | - |
dc.identifier.doi | 10.3390/biomedicines10051130 | - |
dc.identifier.scopusid | 2-s2.0-85130381937 | - |
dc.identifier.wosid | 000801475500001 | - |
dc.identifier.bibliographicCitation | Biomedicines, v.10, no.5, pp.1 - 17 | - |
dc.relation.isPartOf | Biomedicines | - |
dc.citation.title | Biomedicines | - |
dc.citation.volume | 10 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 1 | - |
dc.citation.endPage | 17 | - |
dc.type.rims | ART | - |
dc.type.docType | Review | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Biochemistry & Molecular Biology | - |
dc.relation.journalResearchArea | Research & Experimental Medicine | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Biochemistry & Molecular Biology | - |
dc.relation.journalWebOfScienceCategory | Medicine, Research & Experimental | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | IMMUNOHISTOCHEMISTRY IHC ASSAYS | - |
dc.subject.keywordPlus | PEMBROLIZUMAB PLUS CHEMOTHERAPY | - |
dc.subject.keywordPlus | TUMOR-INFILTRATING LYMPHOCYTES | - |
dc.subject.keywordPlus | T-CELL IMMUNOTHERAPY | - |
dc.subject.keywordPlus | INDOLEAMINE 2,3-DIOXYGENASE | - |
dc.subject.keywordPlus | DOUBLE-BLINDO | - |
dc.subject.keywordPlus | PEN-LABEL | - |
dc.subject.keywordPlus | PD-L1 | - |
dc.subject.keywordPlus | EXPRESSION | - |
dc.subject.keywordPlus | CRYOABLATION | - |
dc.subject.keywordAuthor | immune checkpoint blockade | - |
dc.subject.keywordAuthor | resistance | - |
dc.subject.keywordAuthor | TNBC | - |
dc.identifier.url | https://www.mdpi.com/2227-9059/10/5/1130 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.